Cellular Biomedicine Group Inc., of Shanghai, and GE Healthcare Life Sciences China, said they have established a strategic research collaboration to co-develop certain high-quality industrial control processes in chimeric antigen receptor T-cell (CAR-T) and stem cell manufacturing.